AU2015364253B2 - Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza - Google Patents

Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza Download PDF

Info

Publication number
AU2015364253B2
AU2015364253B2 AU2015364253A AU2015364253A AU2015364253B2 AU 2015364253 B2 AU2015364253 B2 AU 2015364253B2 AU 2015364253 A AU2015364253 A AU 2015364253A AU 2015364253 A AU2015364253 A AU 2015364253A AU 2015364253 B2 AU2015364253 B2 AU 2015364253B2
Authority
AU
Australia
Prior art keywords
administration
influenza
synergistic
reactive antigens
computationally optimized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015364253A
Other languages
English (en)
Other versions
AU2015364253A1 (en
Inventor
Tim ALEFANTIS
Donald Martin Carter Jr.
Christopher Austin Darby
Harold Kleanthous
Ted Milburn ROSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Sanofi Pasteur Inc
Original Assignee
Oregon Health and Science University
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, Sanofi Pasteur Inc filed Critical Oregon Health and Science University
Publication of AU2015364253A1 publication Critical patent/AU2015364253A1/en
Application granted granted Critical
Publication of AU2015364253B2 publication Critical patent/AU2015364253B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015364253A 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza Ceased AU2015364253B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094772P 2014-12-19 2014-12-19
US62/094,772 2014-12-19
PCT/US2015/066882 WO2016100922A1 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

Publications (2)

Publication Number Publication Date
AU2015364253A1 AU2015364253A1 (en) 2017-06-29
AU2015364253B2 true AU2015364253B2 (en) 2020-01-23

Family

ID=56127736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015364253A Ceased AU2015364253B2 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza

Country Status (7)

Country Link
US (2) US10220086B2 (enExample)
EP (1) EP3233116A4 (enExample)
JP (2) JP6764408B2 (enExample)
CN (1) CN107530417A (enExample)
AU (1) AU2015364253B2 (enExample)
CA (1) CA2970158A1 (enExample)
WO (1) WO2016100922A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100922A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019108319A1 (en) * 2017-12-01 2019-06-06 Kemin Industries, Inc. Compositions containing euglena gracilis for viral protection and related methods
WO2019191261A1 (en) * 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
CA3221953A1 (en) * 2021-06-10 2022-12-15 University Of Georgia Research Foundation, Inc. Broadly reactive viral antigens as immunogens, compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
JP2012525370A (ja) * 2009-04-27 2012-10-22 ノバルティス アーゲー インフルエンザに対して防御するためのアジュバント添加ワクチン
IN2014DN07399A (enExample) * 2012-03-30 2015-04-24 Univ Pittsburgh
MX2015005056A (es) * 2012-11-27 2015-07-23 Univ Pittsburgh Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1.
RU2015138530A (ru) * 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
WO2016100922A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
CN108290932A (zh) 2015-06-09 2018-07-17 圣诺菲·帕斯图尔公司 优化编码工程改造的流感蛋白的核苷酸序列的方法
US20200237898A1 (en) 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. M. GILES ET AL, A Computationally Optimized Hemagglutinin Virus-Like Particle Vaccine Elicits Broadly Reactive Antibodies that Protect Nonhuman Primates from H5N1 Infection, THE JOURNAL OF INFECTIOUS DISEASES, 2012, vol. 205(10), pg 1562 *

Also Published As

Publication number Publication date
JP2018501258A (ja) 2018-01-18
US10925957B2 (en) 2021-02-23
US20170368164A1 (en) 2017-12-28
EP3233116A1 (en) 2017-10-25
CA2970158A1 (en) 2016-06-23
US20190175721A1 (en) 2019-06-13
WO2016100922A1 (en) 2016-06-23
JP6764408B2 (ja) 2020-09-30
JP2020186252A (ja) 2020-11-19
CN107530417A (zh) 2018-01-02
EP3233116A4 (en) 2018-05-30
US10220086B2 (en) 2019-03-05
AU2015364253A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
WO2016100926A8 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12016502500B1 (en) Influenza virus vaccines and uses thereof
PH12019501569A1 (en) Universal influenza vaccine compositions
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MY183072A (en) Methods and compositions for inducing protective immunity against filovirus infection
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
PL408649A1 (pl) Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EA201290897A1 (ru) Вакцины для пандемического гриппа
PH12014500369A1 (en) Influenza h5 vaccines
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
IL259451B (en) A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens
ZA201700164B (en) Influenza virus vaccines and uses thereof
HK40013539A (en) Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
HK1173963A (en) Vaccines for pandemic influenza
HK1179177A (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired